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INTRODUCTION 
Desmoid tumors (fibromatosis), are rare locally aggressive tumors 
with less liability of metastasis. They have a high rate of recurrence 
even after complete excision. In patients with familial adeno-
matous polyposis (FAP; Gardner syndrome), desmoid tumors 
tend to be more aggressive and may result in vital organs destruc-
tion and can be fatal. They account for around 0.03% of all neo-
plasms. The incidence is 2–4 million population per year [1]. The 
age of presentation is between 15 and 60 with more females’ predi-
lection [2].
Desmoid tumor occurs more frequently in FAP patients than 
other population with the majority of tumors being intra-abdomi-
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Purpose: Desmoid tumors are locally aggressive tumors with no known potential for metastasis. They tend to recur even after complete exci-
sion. Sometimes it is not easy to differentiate between intra-abdominal desmoid and tumor recurrence, especially after gastrointestinal (GI) 
tumor resection. The current study aims to review the characteristics, management, and outcomes of patients with intra-abdominal desmoid 
tumor post GI resection. 
Methods: During the period between 2007 and 2018, after a retrospective review of patients’ clinical data, 10 patients were finally included. 
Medical records were screened for demographic, clinical, pathological data, management strategy, postoperative morbidity, mortality, recur-
rence rate and follow-up. 
Results: The study comprised 10 patients (8 males). The median age was 53.5 years (range, 35–68 years). Two patients diagnosed as familial 
adenomatous polyposis (FAP). All the patients underwent previous GI resection: three (30%) for colon cancer, three (30%) gastrectomy, two 
(20%) total proctocolectomy with ileal pouch-anal anastomosis (TPC+IPAA) for FAP, one (10%) low anterior resection (three rectal cancers) 
and one (10%) distal pancreatectomy. The tumor was found to be in bowel mesentery in eight cases (80%). The median tumor size was 5.3 
cm (range, 2.6–19.0 cm). Six patients (60%) underwent open resection, while four patients (40%) underwent laparoscopic surgery. Complica-
tions occurred in five cases (50%) and ranged from Clavien-Dindo (II-III). The median follow-up period was 16.5 months (1.5–136.0 months) 
with recurrence in one case (10%). Pathology came out to be desmoid tumor fibromatosis in all cases. 
Conclusion: When a mass develops after surgical resection for abdominal GI malignancy and tends to be large in size, located in the bowel 
mesentery and away from previous primary tumor site, most probably it is desmoid rather than tumor recurrence.
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nal. However, extremity desmoids can also occur [3]. Other risk 
factors include pregnancy, mutation of APC (adenomatous polyp-
osis coli) gene, previous antecedent trauma and family history of a 
desmoid tumor [4,5].
It is not easy to diagnose desmoid tumors before surgical exci-
sion through a biopsy especially if the patient has a previous histo-
ry of abdominal malignancy. It may be difficult to differentiate be-
tween these lesions and disease recurrence or metastasis [6-8].
Most of known about desmoid tumor after previous abdominal 
malignant gastrointestinal (GI) tumors in the literature is in the 
form of case reports. During a routine follow-up after curative re-
section for GI malignancy, computed tomography (CT) and ultra-
sound image sometimes showed a mass in the abdominal cavity. 
Most of them underwent exploration of the abdominal cavity and 
excised for therapeutic and diagnostic purpose. Regarding this 
point, we need to characterize intrabdominal desmoid and need to 
know some clinical characteristics which help to wait and see in 
those patients. 
METHODS
Retrospective study including 10 patients who underwent surgery 
for intra-abdominal desmoid tumor excision in the Department 
of Surgery, Severance Hospital, Yonsei University (Seoul, South 
Korea), between July 2007 and March 2018. The study protocol 
was approved by the Institutional Review Board of Yonsei Univer-
sity (IRB No. 4-2018-1122). Written informed consents were 
waived off because of being retrospective study.
All patients who underwent previous surgical excision for ab-
dominal GI malignancy including stomach, pancreas, colorectal 
with or without FAP were only included. We excluded patients 
with the previous excision of benign intra-abdominal tumors, pa-
tients with extra-abdominal or abdominal wall desmoid.
We collected patients’ demographic data, history and type of 
surgery patient received, diagnostic methods, preoperative carci-
noembryonic antigen (CEA) level, operative details, postoperative 
complications, histopathology follow-up and recurrence rate. 
All patients were suspected for recurrence during routine fol-
low-up, the investigation was done in the form of CT scan for all 
cases (Fig. 1) and positron emission tomography (PET)-CT scan 
for three cases, CEA level (Fig. 2).
RESULTS 
Ten patients were eligible for this study (Tables 1, 2). The median 
age was 53.5 years (range, 35–68 years). Eight (80%) were males. 
Fig. 1. (A, B) Computed tomography showing 28.61-mm mass in the bowel mesentery in a patient post right hemicolectomy for ascending 
colon cancer. The arrow indicates the site of the mass and its size.
A B
Fig. 2. Positron emission tomography-computed tomography 
showing mild fluorodeoxyglucose (FDG) uptake of desmoid mass 
(arrow) at the root of inferior mesenteric artery.
28.61 mm
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tomy with ileal pouch-anal anastomosis (post-TPC+IPAA) for 
rectal cancer on top of FAP and one low anterior resection. Three 
colectomies for colon cancer: two sigmoid and one ascending co-
lon cancer. 
In six patients, desmoid was asymptomatic just detected during 
routine follow up, while in other four patients, two patients were 
presented with intestinal obstruction, one with left upper quadrant 
huge mass around 19 cm and pain, while the last case, desmoid tu-
mor was accidentally discovered in a patient presented with acute 
abdomen and suspected anastomotic leakage post rectal cancer on 
top of FAP. The median time interval of presentation desmoid tu-
mor after previous surgery was 26.5 months (range, 2–216 months).
For the desmoid tumor, the most frequent site for it was the 
small bowel mesentery (Fig. 3) which was seen in eight cases, 
meanwhile, it was retroperitoneal near splenic flexure in one pa-
tient and near the inferior mesenteric artery root in another pa-
tient. So away from the primary tumor site. The median size of the 
tumor was 5.3 cm (range, 2.6–19.0 cm). There was no elevation of 
CEA level in any case and the median preoperative CEA level was 
1.60 (range, 0.43–3.48). No specific findings were noted in the pre-
operative CT scan and even the PET-CT which was done in three 
cases showed mild or increased uptake that why tumor recurrence 
could not be excluded. 
Open excision of the mass was routinely used except in four pa-
tients in whom laparoscopic approach was done. The median op-
erative time was 188 minutes (range, 55–425 minutes), while the 
median blood loss was 25 mL (range, 0–900 mL). Small bowel re-
section was done in six cases. Radical surgery (R0 resection) was 
done in all cases except in the patient who underwent radical sub-
total gastrectomy so, diagnostic laparoscopic frozen biopsy of mul-
tiple masses of small bowel mesentery was done. While, for pallia-
Two with a history of FAP, one male, and one female. All cases un-
derwent previous abdominal surgery for GI malignancy. 
Three patients underwent gastrectomy, two radical total and one 
radical subtotal gastrectomy for stomach cancer. One patient re-
ceived distal pancreatectomy for pancreatic neuroendocrine tu-
mor. Three rectal cancer two of them were post total proctocolec-
Table 1. Patients baseline characteristics   
Characteristic Data
Total no. 10
Age (yr) 53.5 (35–68)
Sex
   Male






   Gastrectomy 
   Colon cancer (2 sigmoid, 1 ascending)
   Rectal cancer (2 TPC+IPAA, 1 LAR)






Time interval of presentation (mo) 26.5 (2–216)
Clinical presentation 
   Asymptomatic (during regular follow-up)
   Intestinal obstruction 
   Abdominal mass and pain







   Small bowel mesentery
   Inferior mesenteric artery root 





Tumor size (cm)   5.3 (2.6–19.0)
CEA level     1.60 (0.43–3.48)
Operation method
   Open 




Operative time (min)    188 (55–425)
Blood loss (mL)    25 (0–900)
Complications
   Fevera)
   Wound infection, dehiscenceb) 
   Ileostomy prolapse: revisionb)






Hospital stay (day)  6 (4–31)
Follow-up period (mo) 16.5 (1.5–136.0)
Recurrence 1 (10)
Mortality 0
Data are presented as median (range) or number (%).  
FAP, familial adenomatous polyposis; TPC+IPAA, total proctocolectomy ileal 
pouch anal anastomosis; LAR, low anterior resection; CEA, carcinoembryonic 
antigen.
a)Clavien-Dindo II. b)Clavien-Dindo III.
Fig. 3. Segment of resected small bowel showing desmoid whitish 
mass 3×3.5 cm (arrow), relatively well delineated located within 
the bowel mesentery.
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tive aim in another patient who underwent exploration for intesti-
nal obstruction after TPC+IPAA for rectal cancer on top of FAP.
Postoperative pathology for all cases was desmoid tumor fibro-
matosis which showed positive B catenin stain. As regard postop-
erative complication, it varies between Clavien-Dindo (II–III), in 
the form of postoperative fever, wound infection and dehiscence, 
one patient had a chest tube and diaphragmatic repair during exci-
sion of a huge tumor near the splenic flexure and one patient had 
ileostomy prolapse. The median length of hospital stay was 6 days 
(range, 4–31 days). There was no mortality. The median follow-up 
period was 16.4 months (range, 1.6–136.1 months), with recur-
rence in one case.
DISCUSSION
Desmoid tumor is a soft tissue tumor that arises in the fascia and 
musculoaponeurotic tissues. It is characterized by fibroblastic pro-
liferation, intercellular space condensation of collagen fibers. Al-
though being histologically benign, the desmoid tumor is clinically 
considered intermediate between a benign and a malignant tumor 
not only due to the lack of surrounding capsule but also because of 
its infiltrative growth pattern. Thus, local recurrence is common, 
but not distant metastasis [9].
Three types of desmoid tumors are identified according to the 
location which include abdominal wall type (49%), extra-abdomi-
nal wall type (43%), and intra-abdominal type (8%) which is the 























1 49 M No Radical total 
 gastrectomy
24 Asymptomatic 




6.8 1.87 Previous abdominal 
 surgery
No No
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No No
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4 57 M No Right 
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5.0 0.92 Previous surgery Wound infection 
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No
7 54 M No Radical total 
 gastrectomy
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5.0 1.66 Previous abdominal 
 surgery
No No
8 53 M No Distal 
 pancreatectomy
30 Abdominal 
 mass and pain
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 near splenic 
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19.0 3.48 Previous abdominal 
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No
9 52 F No Anterior 
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  sigmoid colon 
 cancer 
39 Asymptomatic 
 (routine follow 
 up)
IMA root 2.6 1.68 Previous abdominal 
 surgery
No No











FAP, familial adenomatous polyposis; CEA, carcinoembryonic antigen; M, male; F, female; TPC+IPAA, total proctocolectomy Ileal pouch anal anastomosis; LAR, 
low anterior resection; IMA, inferior mesenteric artery.
90  Korean Journal of Clinical Oncology
least common [1].
As the preoperative diagnosis of intra-abdominal desmoid tu-
mor is difficult with no specific characteristic imaging findings 
[10], so it is difficult to differentiate between desmoid and tumor 
recurrence particularly in patients with previous surgical resection 
of abdominal malignancy. The current study aimed to distinguish 
between desmoid tumors and tumor recurrence.
According to Belliveau and Graham [11], the mean age is 44 ±
16 years and the male to female is 6 to 4 and among patients with 
intra-abdominal desmoid tumors. The most frequent site is the 
small bowel mesentery (72%); of note, 45% of patients have a histo-
ry of abdominal surgery and 22% have Gardner syndrome. In 
comparison to these findings, our current study showed older pa-
tients with a median age of 53.5 years (range, 35–68 years), with 
more male predominance (male:female, 4:1). We also reported the 
same finding that the commonest site of the presentation was 
small bowel mesentery 80%. All patients had previous abdominal 
surgery which is a risk factor for desmoid tumor development. 
Two female patients had a history of FAP.
Intra-abdominal desmoid tumors are often asymptomatic un-
less being large in size. Therefore, when presented, mostly will be 
in the form of an abdominal mass, followed by abdominal disten-
sion, abdominal pain, vomiting and sometimes intestinal obstruc-
tion due to mechanical compression of the tumor [12]. In our 
study most of the cases were asymptomatic and desmoid was acci-
dentally discovered during routine surveillance to rule out tumor 
recurrence. Secondly, emergency presentation in the form of intes-
tinal obstruction in two cases post rectal cancer surgery and peri-
tonitis post rectal cancer on top of FAP and lastly abdominal mass. 
Mesenteric masses have always been a challenge to evaluate ra-
diologically. Ultrasound, CT, magnetic resonance imaging (MRI), 
and PET-CT are typically used to differentiate intra-abdominal tu-
mors. The ultrasound appearance of the desmoid tumor is often a 
hypoechoic mass with internal homogeneity. On CT, a desmoid 
tumor usually appears as a solid mass with an essentially homoge-
neous density, although the degree of enhancement varies among 
tumors. On MRI, a desmoid tumor typically shows high signal in-
tensity or heterogeneous signal intensity on T2-weighted images 
indicating a high density of cellular components, while low signal 
intensity indicates a low density of cellular components and corre-
sponds to the area with abundant collagen [12]. On PET-CT, des-
moid tumors tend to have low fluorodeoxyglucose (FDG) uptake, 
depending on the amount of cellular tissue and mitotic activity of 
fibromatosis [13]. In our study, CT scan cannot rule out tumor re-
currence and most of the reports were in the form of soft tissue 
masses in the small bowel mesentery. PET-CT was done in three of 
our cases which showed mild uptake in one case and increased 
uptake in two cases. 
Shin et al. [14] reported that postoperative intra-abdominal des-
moid tumors can develop up to 7 years after abdominal surgery. 
In our current study, the range of presentation of desmoid post ab-
dominal surgery was from 2 months up to 18 years. The reason for 
this discrepancy may be due to frequent surveillance after resec-
tion of malignant tumors in this study.
The behavior of abdominal desmoid tumors is often unpredict-
able. They can be indolent and spontaneously regress while others 
can be very aggressive with rapid growth and mass effect [15]. 
Even they do not metastasize, they may recur. Some studies quote 
recurrence rates up to 40% [16]. 
Many treatment options for abdominal desmoid tumors are ad-
dressed. Complete surgical excision with wide surgical margins (at 
least 1 cm) is often the first line therapy for resectable tumors 
[10,17]. Most patients require an individualized treatment ap-
proach. Wait and see protocol is also accepted for asymptomatic 
tumors since spontaneous regression and stabilization are possible, 
so sometimes surgical resection is not always necessary [18]. Other 
treatment options other than resection, include radiation and 
pharmacological therapies (nonsteroidal anti-inflammatory drugs 
[NSAIDs], anti-estrogen drugs, molecularly targeted agents and 
anticancer drugs); especially in patients where the desmoid tumor 
is infiltrative with vital structures involvement, or margins are not 
free of the tumor [19,20].
There are hormonal and non-hormonal options for medical 
management. Tamoxifen is often used in combination with 
NSAIDs [15,21]. Tamoxifen is a selective estrogen receptor (ER) 
modulator that inhibits cell proliferation by binding to ER. Alter-
natively, another analog named Raloxifene has been used with pri-
or studies and proved positive results [22]. A partial or complete 
response can be obtained via NSAIDs. Chemotherapy is reserved 
for people who have aggressive nonsurgical tumors or in patients 
after failure of other therapy regimes. Chemotherapy should be 
given in doses individualized to the patient based upon a team ap-
proach. Furthermore, tyrosine kinase inhibitor may be an option 
for treatment in patients who are not a candidate for surgery. Final-
ly, radiation treatment is an option, reserved mainly for extra ab-
dominal tumors due to the risk of radiation-induced injury to in-
tra-abdominal structures, as radiation-induced enteritis [23]. In 
our study and as recurrence of malignancy was suspected so surgi-
cal resection to confirm the histopathology was mandatory to 
avoid unnecessary systemic chemotherapy.
Though the overall prognosis of patients with desmoid tumors 
not associated with FAP is relatively good [24], the recurrence and 
mortality rates of desmoid tumor patients with FAP are 22%–85% 
and 10%–60%, respectively [25]. Thus, an elevated risk of recur-
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rence should be considered even after surgery, and regular fol-
low-up is required for early detection of recurrence.
During follow-up of patients after GI surgery with CT scan, we 
sometimes find intra-abdominal mass anywhere in the abdominal 
cavity, at that time, we must differentiate it from tumor recurrence. 
We found the clinical characteristics of benign desmoid tumor and 
it may help to predict intra-abdominal desmoid tumor after sur-
gery for GI tract cancer. The clinical characteristics of desmoid tu-
mors include; being large sized soft tissue oval or rounded mass 
with less uptake in PET-CT scan, usually located away from pri-
mary tumor resection site, not associated with CEA level elevation 
(Table 3) [26].
In patients with a history of surgery for intra-abdominal malig-
nancies, it may be difficult to distinguish the tumor recurrence 
from the desmoid tumor. However, the possibility of desmoid tu-
mors should be into consideration. Desmoid tumors tend to be 
large in size, CEA level is normal and located in the bowel mes-
entery and away from the previous primary tumor site. 
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